A Really Near-Term Application for Discovery Technology: Momenta and Sandoz Attempt a Biogeneric

The press release was foggy; Sandoz Inc., the generics unit of Novartis AG, was teaming up with a biotech, Momenta Pharmaceuticals Inc. to commercialize "complex pharmaceutical products." Upon closer examination, the deal in fact has wide-ranging implications, representing the very real near-term possibility of a true generic biologic,